NEW YORK, July 31 – Lexicon Genetics of The Woodlands, Texas, said Tuesday it had signed a two-year deal to provide Immunex with knockout mammalian models for the pharmaceutical company’s drug development program.

In exchange, Lexicon will receive an up-front technology access fee, annual research funding, and milestone and royalty payments on products developed through the collaboration.

Lexicon did not disclose the specific financial terms of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.